244 related articles for article (PubMed ID: 18191875)
1. CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies.
Boström F; Hansson O; Gerhardsson L; Lundh T; Minthon L; Stomrud E; Zetterberg H; Londos E
Neurobiol Aging; 2009 Aug; 30(8):1265-71. PubMed ID: 18191875
[TBL] [Abstract][Full Text] [Related]
2. Speciation analysis of selected metals and determination of their total contents in paired serum and cerebrospinal fluid samples: An approach to investigate the permeability of the human blood-cerebrospinal fluid-barrier.
Nischwitz V; Berthele A; Michalke B
Anal Chim Acta; 2008 Oct; 627(2):258-69. PubMed ID: 18809082
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T
Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286
[TBL] [Abstract][Full Text] [Related]
4. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies.
Boström F; Hansson O; Blennow K; Gerhardsson L; Lundh T; Minthon L; Zetterberg H; Londos E
Dement Geriatr Cogn Disord; 2009; 28(4):314-9. PubMed ID: 19844105
[TBL] [Abstract][Full Text] [Related]
6. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
Noguchi-Shinohara M; Tokuda T; Yoshita M; Kasai T; Ono K; Nakagawa M; El-Agnaf OM; Yamada M
Brain Res; 2009 Jan; 1251():1-6. PubMed ID: 19071095
[TBL] [Abstract][Full Text] [Related]
7. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
[TBL] [Abstract][Full Text] [Related]
8. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
10. Metal concentrations in plasma and cerebrospinal fluid in patients with Alzheimer's disease.
Gerhardsson L; Lundh T; Minthon L; Londos E
Dement Geriatr Cogn Disord; 2008; 25(6):508-15. PubMed ID: 18463412
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders.
Spies PE; Melis RJ; Sjögren MJ; Rikkert MG; Verbeek MM
J Alzheimers Dis; 2009; 16(2):363-9. PubMed ID: 19221426
[TBL] [Abstract][Full Text] [Related]
12. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
[TBL] [Abstract][Full Text] [Related]
13. Concentrations of metals, beta-amyloid and tau-markers in cerebrospinal fluid in patients with Alzheimer's disease.
Gerhardsson L; Blennow K; Lundh T; Londos E; Minthon L
Dement Geriatr Cogn Disord; 2009; 28(1):88-94. PubMed ID: 19672066
[TBL] [Abstract][Full Text] [Related]
14. Reduced CSF CART in dementia with Lewy bodies.
Schultz K; Wiehager S; Nilsson K; Nielsen JE; Lindquist SG; Hjermind LE; Andersen BB; Wallin A; Nilsson C; Petersén A
Neurosci Lett; 2009 Apr; 453(2):104-6. PubMed ID: 19356602
[TBL] [Abstract][Full Text] [Related]
15. Altered CSF orexin and α-synuclein levels in dementia patients.
Wennström M; Londos E; Minthon L; Nielsen HM
J Alzheimers Dis; 2012; 29(1):125-32. PubMed ID: 22207004
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
[TBL] [Abstract][Full Text] [Related]
17. CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.
Mollenhauer B; Esselmann H; Trenkwalder C; Schulz-Schaeffer W; Kretzschmar H; Otto M; Wiltfang J; Bibl M
J Alzheimers Dis; 2011; 24(2):383-91. PubMed ID: 21297274
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances alpha-synuclein fibril formation in vitro.
Ono K; Noguchi-Shinohara M; Yoshita M; Naiki H; Yamada M
Exp Neurol; 2007 Feb; 203(2):579-83. PubMed ID: 17011551
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias.
Maetzler W; Berg D; Synofzik M; Brockmann K; Godau J; Melms A; Gasser T; Hörnig S; Langkamp M
J Alzheimers Dis; 2011; 26(1):171-9. PubMed ID: 21593566
[TBL] [Abstract][Full Text] [Related]
20. Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.
Ishiki A; Kamada M; Kawamura Y; Terao C; Shimoda F; Tomita N; Arai H; Furukawa K
J Neurochem; 2016 Jan; 136(2):258-61. PubMed ID: 26485083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
